Piramal Invests Almost $75m In Expanding Manufacturing Capacity
Company Expects Part Of Its UK Manufacturing Site To Be Functional By Next Year
Piramal Pharma’s Piramal Pharma Solutions contract development and manufacturing organization has invested around $75m in expanding its antibody-drug conjugate capabilities at its Grangemouth facility in Scotland and investing in a new active pharmaceutical ingredient infrastructure at the Morpeth facility in England.
